teach me myasthenia gravis conultant level and at the end of dicusion also design mcqs for better understanding evaluation

Reading File

Now let me search the medical library comprehensively for myasthenia gravis content, running parallel queries across multiple topics.

Finding Sources

Searching PubMed

"myasthenia gravis"[MeSH Terms] AND treatment

Searching the Web

myasthenia gravis consultant level review 2024 2025 pathophysiology diagnosis treatment

Excellent - Bradley and Daroff's Neurology and Henry's Laboratory textbooks have the most detailed MG content. Let me read all the key sections in parallel.

Reading File

Finding Sources

Excellent content. Now let me read the main Bradley & Daroff MG chapter (block 29) which has the full dedicated section, plus Goldman-Cecil for comprehensive management.

Reading File

Excellent content. Let me continue reading the Bradley & Daroff block 29 for diagnosis, management, and crisis sections:

Reading File

I have extensive rich content. Let me also quickly fetch the key clinical images and read the treatment/crisis section from Bradley & Daroff block 29 (which was partially truncated):

Loading Image

Finding Sources

I now have comprehensive, high-quality content from multiple authoritative textbooks. Let me compile the complete consultant-level teaching document now.---

Myasthenia Gravis - Consultant-Level Teaching

1. Definition and Overview

Myasthenia gravis (MG) is the most common primary disorder of neuromuscular transmission (NMT). It is an acquired autoimmune disease where autoantibodies bind to postsynaptic proteins - most commonly the nicotinic acetylcholine receptor (AChR) - at the neuromuscular junction (NMJ), disrupting normal transmission and causing fatigable skeletal muscle weakness. The hallmark: weakness that worsens with activity and improves with rest.

"MG has been named 'the great imitator' because its symptoms can mimic many other chronic neurologic disorders." - Tintinalli's Emergency Medicine

2. Epidemiology

Feature	Detail
Prevalence (US)	~20/100,000 (~60,000 patients total)
Sex distribution	Females 3x more often before age 40; males predominate after age 50
Age at onset	Bimodal: young women (20s-30s) and older men (60s-70s)
Trend	Increasing prevalence over 50 years - more elderly patients now affected
Thymoma association	~10% of MG patients have thymoma; 1/3 of thymoma patients develop MG
Genetic predisposition	~5% of patients have a family member with MG; heritability index ~0.65

HLA associations:

Early-onset females: HLA-A1, B8, DRw3
Late-onset males: HLA-A3, B7, DRw2.1

3. Pathophysiology

3.1 Normal Neuromuscular Junction

The NMJ converts the nerve's small electrical signal into a chemical one (via ACh), then back to an electrical signal large enough to trigger muscle contraction. In health, there is a large safety factor - ACh release generates end-plate potentials far exceeding the threshold for action potential generation.

3.2 The Three Mechanisms of Antibody-Mediated Damage

This is the key diagram from Goldman-Cecil Medicine:

Three mechanisms of AChR antibody damage in MG - direct block, cross-linking/internalization, and complement-mediated lysis

1. Direct blocking: AChR-Abs occupy the ACh binding site, competitively blocking ACh attachment and ion channel opening.

2. Cross-linking and modulation: Divalent antibodies cross-link adjacent AChRs, accelerating their internalization and degradation - reducing total receptor number.

3. Complement-mediated lysis: AChR-Abs activate complement, causing structural damage to the postsynaptic membrane ("simplification" of the junctional folds) and physical loss of AChRs. This is the most important overall mechanism in AChR-antibody MG.

The net result: reduced functional AChRs → decreased end-plate potential amplitude → failure to reach action potential threshold → muscle fiber dropout → fatigable weakness. With repeated stimulation, ACh stores are depleted and the already-small end-plate potential declines further (decremental response on EMG).

3.3 Role of the Thymus

The thymus is abnormal in ~80% of MG patients:

Thymic hyperplasia (65%): Active germinal centers with autoreactive B cells producing AChR-Abs. The thymus likely initiates the breakdown in immune tolerance.
Thymoma (10-15%): Deficiency of AIRE protein → defective negative selection → failure to eliminate autoreactive T cells. These escape to the periphery and stimulate B cells to produce AChR-Abs.
Thymic atrophy: Seen in late-onset MG.

4. Antibody Subtypes and Clinical Correlation

Antibody	Frequency	Key Features
Anti-AChR	80-90% generalized MG; 50% ocular MG	Binding, blocking, modulating subtypes; IgG1/IgG3; complement-fixing
Anti-MuSK	30-50% of AChR-negative GMG	IgG4; no complement activation; prominent bulbar/facial/respiratory; worsened by ChEI
Anti-LRP4	1-3% all MG	Mild-moderate disease
Anti-titin / Anti-RyR	Associated with thymoma-MG and LOMG	Marker of severity; frequent myasthenic crises
Seronegative	~5-10%	Double-seronegative; SFEMG most useful

Clinical pearls for MuSK-MG:

Predominantly female, equatorial geographic distribution
Facial, bulbar, neck, and respiratory muscles disproportionately affected with prominent atrophy
Many patients worsen with pyridostigmine (profuse fasciculations)
Responds well to plasma exchange and rituximab
Not associated with thymoma - thymectomy NOT indicated

5. Clinical Subtypes (MGFA Classification Framework)

5.1 Ocular MG (OMG)

Confined to ptosis and diplopia only
~15% of Caucasian MG patients; up to 58% in Asian populations
If weakness stays ocular for 2 years → 90% chance it will remain ocular (never generalizes)
AChR-Abs often negative; RNS studies often negative → SFEMG required
More common in Asian populations

5.2 Generalized MG (GMG)

Early-Onset (EOMG, <50 years):

Predominantly female
Thymic hyperplasia
Anti-AChR positive
HLA-A1, B8, DRw3

Late-Onset (LOMG, >50 years):

Predominantly male
Atrophic thymus
May have additional anti-titin / anti-RyR antibodies
More severe, frequent crises

Thymomatous MG:

Equal sex distribution
Peak age 50
Anti-titin and anti-RyR commonly positive
May occur at any age
Thymectomy mandatory but does NOT cure MG

6. Clinical Presentation

Ocular features are the presenting symptom in ~2/3 of patients:

Ptosis - characteristically fatigable; worsens with sustained upgaze
Diplopia - variable, non-conforming to single CN pattern (MG mimics any pattern of ophthalmoplegia)
Cogan's lid twitch - on re-fixation from downgaze, the lid briefly overshoots then droops

Ocular motility abnormalities in MG showing ptosis, upgaze limitation, and lateral gaze deficits

Note: Asymmetric ptosis, asymmetric ophthalmoplegia not conforming to a single cranial nerve. The forehead furrows asymmetrically as the patient tries to compensate.

Bulbar weakness:

Dysphagia (particularly with tough foods; jaw fatigue during a meal)
Nasal voice (dysphonia) - worsens with prolonged speech
Dysarthria
Neck extensor weakness ("head drop")

Key examination features:

Fatigable weakness (unlike fixed weakness of UMN or myopathy)
Normal tendon reflexes (key differentiating feature from LEMS and MND)
Normal sensation
No autonomic involvement (unlike LEMS)
Weakness typically worst at end of day

Diurnal fluctuation: Weakness least in the morning, worst in the evening - the classic pattern that suggests MG.

7. Diagnosis

7.1 Clinical Assessment Tools

Ice pack test: Ice applied to closed eyelid for 2 minutes → cooling slows AChE, improves ptosis. Sensitivity ~80%, specificity ~97% for ocular MG. Simple, safe bedside test.

Sleep test: Rest for 30 minutes with eyes closed → improvement in ptosis. Less well-validated.

Fatigability testing: Sustained upgaze for 60 seconds → progressive ptosis; arm abduction for 2 minutes.

7.2 Pharmacological Testing

Edrophonium (Tensilon) test:

Short-acting AChEI; onset 30 sec, duration 5 min
Test dose 2 mg IV, then 8 mg IV if no response
Positive: objective improvement in ptosis, diplopia, or weakness
Risks: bradycardia, bronchospasm; resuscitation equipment mandatory; atropine at bedside
Sensitivity ~80-90% for generalized MG; lower for ocular or MuSK MG

7.3 Serological Testing

Test	Sensitivity	Notes
AChR binding Ab	~85-90% GMG	Most sensitive single test
AChR blocking Ab	~50-60%	Used with binding
AChR modulating Ab	~90%	Cross-links and internalizes AChR
Anti-MuSK Ab	30-50% of AChR-neg	RIA; IgG4
Anti-LRP4 Ab	1-3%
Anti-titin / Anti-RyR	Variable	Suggests thymoma; marker of severity

From Henry's Clinical Diagnosis: "AChR-Ab tests for binding, blocking, and modulating are available. Binding AChR-Ab fixes complement. Blocking AChR-Ab interferes with ACh attachment. Modulating AChR-Ab causes internalization of the AChR."

Important: Antibody titers do not reliably correlate with disease severity between patients, but changes in a single patient's titer can reflect treatment response.

7.4 Electrodiagnostic Studies

Repetitive Nerve Stimulation (RNS):

Low frequency stimulation (2-3 Hz) of proximal muscles (deltoid, trapezius, facial)
Positive: >10% decrement in CMAP amplitude between 1st and 4th/5th response
Sensitivity: ~75-90% for GMG; only ~50% for OMG
Key: Must examine proximal muscles - distal muscles often normal

Single-Fiber EMG (SFEMG):

Gold standard electrophysiological test
Measures "jitter" (variability in neuromuscular transmission timing between paired fibers)
Sensitivity: >95% for GMG; 85-95% for OMG
May show "blocking" (complete failure of transmission) in severe cases
Not specific for MG (abnormal in any NMJ disease)
Most useful when seronegative

7.5 Imaging

CT chest (mandatory in all newly diagnosed MG):

Rule out thymoma - present in 10-15%
If CT inconclusive, MRI chest
Thymoma requires surgical resection regardless of MG severity

8. Differential Diagnosis

Condition	Key Distinguishing Features
Lambert-Eaton Myasthenic Syndrome	Presynaptic; proximal lower limb > upper; reduced reflexes restored with repeated stimulation (post-tetanic potentiation); associated with SCLC; autonomic dysfunction; incremental RNS response
Botulism	Fixed dilated pupils; descending paralysis; presynaptic; no antibodies to AChR
Oculopharyngeal muscular dystrophy	Slowly progressive; family history; genetic mutation (PABPN1); no fatigability
Mitochondrial myopathy (CPEO)	Ptosis + ophthalmoplegia but no diplopia; retinal pigment changes; lactic acidosis
Graves' ophthalmopathy	Proptosis; lid lag; thyroid function abnormalities
Miller-Fisher syndrome	Post-infectious; areflexia; GQ1b antibodies; ataxia
Intracranial mass	Cranial nerve palsies - conform to single nerve territory; imaging abnormality

9. Treatment

9.1 Symptomatic Treatment - Acetylcholinesterase Inhibitors (ChEI)

Pyridostigmine (Mestinon): First-line symptomatic treatment for all subtypes except MuSK-MG.

Standard dose: 30-60 mg every 4-6 hours (max ~480 mg/day)
Onset 30-45 min, duration ~4 hours
Mechanism: Inhibits AChE → increases ACh in synaptic cleft → more receptor occupancy
Side effects: Muscarinic (GI cramps, diarrhoea, hypersalivation, bradycardia); nicotinic (fasciculations, muscle cramps)
Does NOT address the underlying autoimmune process
In MuSK-MG: use with caution - many patients worsen (fasciculations, cholinergic crisis)

9.2 Rapid Immunomodulation (for acute exacerbations and crisis)

Plasma Exchange (PLEX / Plasmapheresis):

Removes circulating AChR-Abs directly
Protocol: 5-6 exchanges over 10-14 days (3 liters per exchange)
Onset of benefit: days
Duration of benefit: 4-8 weeks
Evidence supports PLEX over IVIG for myasthenic crisis (greater short-term efficacy, faster onset)
Preferred pre-thymectomy to optimize neuromuscular function

Intravenous Immunoglobulin (IVIG):

Mechanism: Fc receptor saturation; anti-idiotype antibodies; complement inhibition
Dose: 2 g/kg over 5 days (or 1 g/kg x 2 days)
Onset: 5-10 days
Duration: 4-8 weeks
Equal overall efficacy to PLEX for non-crisis MG exacerbation
Preferred in patients with poor venous access, cardiovascular instability, or coagulopathy
Less preferred than PLEX in true myasthenic crisis (slower onset)

9.3 Long-Term Immunosuppression

Corticosteroids (Prednisone):

Most rapidly effective long-term immunosuppressant
Dose: Start low (20 mg/day) and increase gradually - abrupt high-dose start can precipitate transient worsening
Titrate to effect; typical maintenance 10-20 mg/day or alternate-day dosing
Benefit seen in 70-80% of patients
Limitations: Cushing syndrome, osteoporosis, DM, cataracts with long-term use
Co-prescribe: calcium, vitamin D, PPI, bone protection agent

Azathioprine:

Purine analogue; T and B cell suppression
Dose: 2-3 mg/kg/day
Check TPMT enzyme activity before starting (poor metabolizers → toxicity)
Onset of benefit: 6-18 months (major limitation - "steroid-sparing" agent)
Side effects: GI intolerance, hepatotoxicity, myelosuppression, increased malignancy risk
Flu-like reaction in first weeks (idiosyncratic)

Mycophenolate Mofetil (MMF):

Inhibits IMPDH; selective lymphocyte antiproliferation
Dose: 1000-1500 mg BD
Onset: 4-12 months
Better GI tolerability than azathioprine
Teratogenic - avoid in pregnancy

Cyclosporine / Tacrolimus:

Calcineurin inhibitors; block IL-2 dependent T cell activation
More rapidly effective than azathioprine (~3 months)
Tacrolimus: 3 mg/day; monitored by trough levels
Side effects: nephrotoxicity, hypertension, neurotoxicity

Methotrexate:

Alternative steroid-sparing agent; weekly dosing
Folic acid supplementation mandatory

Rituximab:

Anti-CD20 monoclonal antibody (B cell depleting)
Particularly effective in MuSK-MG (often disease-modifying)
Used in refractory AChR-positive MG
2025 Cochrane systematic review confirms benefit (PMID 40607605)
Dosing: 375 mg/m² weekly x4, or 1g x2 two weeks apart
Monitor for PML, infections

9.4 Complement Inhibition - Eculizumab

Terminal complement inhibitor (C5 inhibitor); blocks membrane attack complex formation
Approved for AChR-antibody positive refractory generalized MG
ADAPT trial: significant improvement in MG-ADL scores vs. placebo
Dosing: IV infusion every 2 weeks after initial loading
Mandatory meningococcal vaccination ≥2 weeks before first dose
Ravulizumab (longer-acting C5 inhibitor, every 8-week dosing): also approved

9.5 FcRn Inhibitors - Novel Targeted Therapies

Efgartigimod:

Blocks neonatal Fc receptor (FcRn) → accelerates IgG catabolism → reduces all IgG antibodies including AChR-Ab
ADAPT trial positive for both AChR-positive and AChR-negative MG
IV formulation: 10 mg/kg weekly x4 cycles; repeat cycles PRN

Rozanolixizumab, nipocalimab: Additional FcRn inhibitors in development / recent approval pipeline.

A 2025 network meta-analysis (PMID 40346603) comparing biologics confirms superior efficacy of complement inhibitors and FcRn blockers over conventional therapy in refractory generalized MG.

9.6 Thymectomy

Indications:

All thymoma patients - mandatory regardless of MG severity
Non-thymomatous AChR-positive GMG aged 18-65: strongly recommended following the landmark MGTX trial (2016) showing improved outcomes vs. medical therapy alone over 3 years
Generally not indicated in: MuSK-MG, seronegative MG, OMG, age <18 or >65, late-onset with atrophic thymus (debated)

Surgical approach: Video-assisted thoracoscopic surgery (VATS) or robotic; extended transsternal thymectomy for thymoma.

Pre-operative optimization: PLEX or IVIG to maximize pre-operative neuromuscular function.

Outcome: 30-40% of non-thymomatous patients achieve complete stable remission (CSR); ~50% achieve minimal manifestations. Benefit may take 1-3 years to become apparent.

10. Myasthenic Crisis

Definition

Life-threatening weakness sufficient to require mechanical ventilation or intubation, or prevent adequate swallowing. This is a medical emergency.

Precipitants (the "PIRATES" triggers to remember)

P - Pregnancy / peripartum
I - Infection (most common trigger - respiratory infections)
R - Reduction / rapid tapering of immunosuppression
A - Aspiration / surgery / stress
T - Thyroid dysfunction
E - Emotional/psychological stress
S - Specific drugs (see below)

Drugs That Precipitate Myasthenic Crisis

Category	Drugs
Antibiotics	Aminoglycosides, fluoroquinolones, macrolides, tetracyclines
Cardiovascular	Beta-blockers, calcium channel blockers, procainamide, quinidine
Neuromuscular blockers	Succinylcholine, vecuronium (prolonged effect)
Antiepileptics	Phenytoin, carbamazepine
Psychotropics	Chlorpromazine, lithium
Other	D-penicillamine (can actually cause MG), iodinated contrast, magnesium

Myasthenic Crisis vs. Cholinergic Crisis

Feature	Myasthenic Crisis	Cholinergic Crisis
Cause	Under-treated MG / precipitant	AChEI overdose
Pupils	Normal	Miotic (pinpoint)
Secretions	Normal/decreased	Increased (SLUDGE)
Fasciculations	Absent	Present
Edrophonium test	Improves weakness	Worsens or no change
Treatment	PLEX/IVIG + vent support	Stop AChEI + atropine

Management of Myasthenic Crisis

Airway first: NIV may be appropriate for mild-moderate respiratory compromise (FVC > 20 mL/kg); intubate if FVC <15 mL/kg, PaO₂ <70, or rapidly deteriorating. The "20-30 rule": intubate when FVC falls below 20 mL/kg, NIF (negative inspiratory force) less negative than -30 cmH₂O.
Hold pyridostigmine during crisis (secretions worsen, difficult to differentiate from cholinergic worsening in intubated patients)
PLEX (preferred): 5-6 exchanges over 2 weeks; 95% efficacy; preferred by most experts over IVIG for acute crisis
IVIG (alternative): 2 g/kg over 5 days; equal efficacy in non-crisis exacerbations; preferred if PLEX contraindicated
High-dose corticosteroids: IV methylprednisolone, then transition to oral prednisone. Note: Initial steroid therapy can paradoxically worsen weakness in first 1-2 weeks.
ICU monitoring: Respiratory function (FVC, NIF every 4 hours), aspiration precautions, DVT prophylaxis
Treat underlying precipitant (infection, medication)

11. Special Populations

11.1 MG in Pregnancy

Pregnancy can worsen (1st trimester, post-partum) or improve (2nd trimester) MG
AChR-Abs cross the placenta → neonatal MG in 10-20% of babies (transient, clears in weeks as maternal antibodies decay)
Safe medications: pyridostigmine, IVIG, prednisone, azathioprine (avoid in 1st trimester)
Avoid: MMF (teratogenic), methotrexate (teratogenic)
Mode of delivery: Normal vaginal delivery preferred; uterine smooth muscle not affected. 2nd stage can be prolonged - augment if needed.
Neonatal MG: feeding difficulty, hypotonia, respiratory distress - treat with neostigmine NG

11.2 MG in the Elderly

Most common new-onset MG subgroup now
Late-onset MG - consider thymoma imaging
Beware drug interactions and polypharmacy exacerbations
Higher risk of aspiration, infections, steroid side effects
Newer FcRn inhibitors and eculizumab offer targeted options

12. Monitoring and Outcome Measures

MGFA Classification (Class I-V):

Class I: Ocular only
Class II: Mild generalized (IIa limb/axial, IIb bulbar/respiratory)
Class III: Moderate generalized
Class IV: Severe generalized
Class V: Intubation required

MG-ADL Scale: Patient-reported; 8 items; most validated for clinical trials (eculizumab, efgartigimod trials)

QMG Score: Quantitative Myasthenia Gravis Score - physician-administered; 13 items; gold standard for clinical assessment

Treatment goals:

Complete Stable Remission (CSR): no symptoms or signs of MG for ≥12 months on no medications
Pharmacological Remission (PR): no symptoms or signs on medication
Minimal Manifestations (MM): no functional limitation despite some exam findings

13. Comparison: MG vs. Lambert-Eaton Myasthenic Syndrome (LEMS)

Feature	MG	LEMS
Site of defect	Postsynaptic	Presynaptic
Antibody	Anti-AChR (80-90%)	Anti-VGCC (P/Q type) (85%)
Weakness pattern	Ocular/bulbar first; proximal limbs	Proximal legs first; spares ocular/bulbar early
Reflexes	Normal	Reduced/absent (restored post-exercise)
Autonomic	Absent	Present (dry mouth, constipation, erectile dysfunction)
Malignancy	Thymoma (10-15%)	SCLC (40-60%) - paraneoplastic
RNS	Decrement at low frequency	Increment at high frequency (>100% increase)
Response to ChEI	Improves	Minimal benefit

14. Recent Advances (2024-2025)

FcRn inhibitors (efgartigimod, rozanolixizumab, nipocalimab): Rapidly reduce all IgG subclasses, achieving faster effects. Efgartigimod now FDA-approved for both IV and subcutaneous formulations.
Ravulizumab: Long-acting C5 inhibitor (every 8 weeks vs. eculizumab every 2 weeks).
CAR-T cell therapy (Descartes-08, targeting BCMA on plasma cells): Early phase data showing deep and potentially durable remission. Being watched as a potential disease-modifying/curative approach.
Rituximab Cochrane review (2025, PMID 40607605): Confirms benefit for refractory MG, especially MuSK-positive.
Network meta-analysis (2025, PMID 40346603): Demonstrates superior efficacy of FcRn inhibitors and complement inhibitors over conventional agents in refractory generalized MG.

MCQ Evaluation - Consultant Level

Q1. A 28-year-old woman presents with 3 months of intermittent ptosis and diplopia, worse in the evening. Examination shows fatigable ptosis on sustained upgaze. Which antibody, if positive, is most sensitive for detecting her likely diagnosis?

A) Anti-MuSK antibody
B) Anti-AChR blocking antibody
C) Anti-AChR modulating antibody
D) Anti-LRP4 antibody
E) Anti-titin antibody

Answer: C - Anti-AChR modulating antibody has the highest sensitivity (~90%) among AChR antibody subtypes, as it detects antibodies that cause receptor internalization and degradation. Anti-AChR binding is most commonly ordered (85-90% sensitivity overall), but modulating provides the highest individual sensitivity. Anti-MuSK is relevant only in AChR-negative patients. Anti-titin suggests thymoma-associated MG.

Q2. A 65-year-old male with AChR-Ab positive myasthenia gravis develops respiratory failure. On examination, pupils are miotic, he has profuse oral secretions, fasciculations, and diarrhoea. What is the most appropriate immediate management?

A) Increase pyridostigmine dose and administer IVIG
B) Perform plasma exchange immediately
C) Stop pyridostigmine, administer IV atropine, provide ventilatory support
D) Administer edrophonium chloride as a diagnostic test
E) Intubate and start high-dose corticosteroids

Answer: C - The clinical picture describes cholinergic crisis (miosis, SLUDGE: Salivation, Lacrimation, Urination, Defecation/Diarrhoea, GI upset, Emesis; fasciculations) caused by acetylcholinesterase inhibitor overdose. Management is to STOP the AChEI and administer IV atropine (antimuscarinic) along with ventilatory support. Performing edrophonium (also an AChEI) would worsen the crisis. PLEX/IVIG is for myasthenic crisis (insufficient cholinergic stimulation).

Q3. A 45-year-old woman with known MG is found to have a 4 cm anterior mediastinal mass on CT chest. Serologies show AChR-Ab, anti-titin, and anti-ryanodine receptor antibodies. What is the most appropriate next management step?

A) Commence rituximab and reassess in 6 months
B) Thymectomy regardless of MG disease severity
C) Radiotherapy to the mediastinal mass
D) Plasma exchange followed by observation
E) Thymectomy only if MG is refractory to medical therapy

Answer: B - A thymoma is a surgical indication regardless of MG severity or control status. The combination of AChR-Ab, anti-titin, and anti-ryanodine receptor antibodies is characteristic of thymoma-associated MG. While thymectomy will not cure the autoimmune process (MG persists), it removes the tumour, which can invade locally and carry malignant potential. Pre-operative PLEX/IVIG should be considered to optimise respiratory function.

Q4. Which electrodiagnostic finding is most specific to myasthenia gravis versus Lambert-Eaton myasthenic syndrome?

A) Decreased CMAP amplitude on baseline recording
B) >10% decrement on 3 Hz repetitive nerve stimulation
C) >100% increment on 50 Hz repetitive nerve stimulation
D) Increased jitter on single-fiber EMG
E) Spontaneous fibrillations on needle EMG

Answer: B - A >10% decrement on low-frequency (2-3 Hz) RNS is characteristic of postsynaptic NMJ disease (MG). In LEMS (presynaptic), the typical finding is a significant increment (>100%) on high-frequency stimulation (50 Hz) or post-exercise facilitation. Increased jitter on SFEMG (Answer D) is sensitive for NMJ disease but not specific - it is elevated in both MG and LEMS. Fibrillations are not characteristic of MG.

Q5. A 35-year-old woman with MuSK-antibody positive myasthenia gravis has worsening bulbar weakness despite pyridostigmine 60 mg 5 times daily. She has profuse fasciculations. What is the most appropriate treatment adjustment?

A) Increase pyridostigmine to 90 mg 6 times daily
B) Add neostigmine IV
C) Reduce or stop pyridostigmine; initiate plasma exchange and rituximab
D) Add azathioprine and continue current pyridostigmine dose
E) Perform thymectomy

Answer: C - In MuSK-MG, cholinesterase inhibitors (pyridostigmine) often worsen symptoms and cause profuse fasciculations. This patient is showing signs of over-medication despite inadequate disease control. Pyridostigmine should be reduced or stopped. MuSK-MG responds well to plasma exchange (short-term) and rituximab (B cell depletion, given the IgG4 nature of the antibody). Thymectomy is NOT indicated in MuSK-MG.

Q6. The mechanism by which eculizumab treats refractory AChR-Ab positive myasthenia gravis is:

A) Blocking AChR antibody production by plasma cells
B) Inhibiting T-helper cell activation via calcineurin pathway
C) Preventing C5 cleavage, blocking formation of the membrane attack complex
D) Reducing total IgG by blocking neonatal Fc receptor recycling
E) Binding to AChR to prevent autoantibody attachment

Answer: C - Eculizumab is a monoclonal antibody that binds complement protein C5, preventing its cleavage into C5a and C5b, thus blocking terminal complement activation and membrane attack complex (MAC) formation. This directly addresses the most important pathogenic mechanism in AChR-Ab positive MG - complement-mediated lysis of the postsynaptic membrane. Option D describes the mechanism of FcRn inhibitors (efgartigimod). Option B describes calcineurin inhibitors (cyclosporine/tacrolimus).

Q7. A 22-year-old Asian man presents with isolated ptosis and diplopia for 18 months. Workup shows negative AChR-Ab, normal RNS, but increased jitter on SFEMG of the orbicularis oculi. CT chest is normal. He has been symptom-free for 2 years with pyridostigmine alone. What is the most accurate prognosis statement?

A) He will definitely develop generalized weakness within 5 years
B) He has a 90% probability of remaining ocular-only since symptoms have been confined to ocular muscles beyond 2 years
C) Negative AChR-Ab makes the diagnosis unlikely; another cause should be sought
D) His Asian ethnicity means he has a lower risk of ocular MG
E) Thymectomy should be performed to prevent generalization

Answer: B - If myasthenic weakness remains limited to the ocular muscles for 2 years, there is a 90% likelihood that the disease will not generalize (Bradley & Daroff). This patient has passed the 2-year mark. Asian populations actually have a HIGHER prevalence of ocular MG (up to 58% vs. 10-15% in Caucasians). Negative AChR-Ab is common in ocular MG (~50%); SFEMG positive confirms the diagnosis. Thymectomy is generally not recommended for pure ocular MG.

Q8. Which of the following is the most appropriate first-line treatment for myasthenic crisis when plasma exchange is not available?

A) IV methylprednisolone 1g daily
B) Oral prednisone 80 mg daily
C) IVIG 2 g/kg over 5 days
D) IV pyridostigmine infusion
E) SC injection of neostigmine

Answer: C - IVIG (2 g/kg over 5 days) is the recommended alternative to plasma exchange for myasthenic crisis when PLEX is unavailable or contraindicated (poor venous access, hemodynamic instability, coagulopathy). High-dose steroids (A and B) can paradoxically worsen weakness in the first 1-2 weeks when started acutely in crisis and are a secondary measure - not first-line for acute crisis management. IV pyridostigmine and neostigmine only provide symptomatic relief and do not address the underlying immune attack.

Q9. During the assessment of a patient with suspected myasthenic crisis, which ventilatory parameter most reliably guides the decision to intubate?

A) PaO₂ < 80 mmHg on room air
B) SpO₂ < 95%
C) Forced vital capacity (FVC) < 15-20 mL/kg
D) Respiratory rate > 25/min
E) PaCO₂ > 40 mmHg

Answer: C - The "20-30 rule" in neuromuscular respiratory failure: intubation should be strongly considered when FVC falls below 20 mL/kg and negative inspiratory force (NIF) becomes less negative than -30 cmH₂O. PaO₂ and SpO₂ are insensitive early markers - hypoxia is a late sign because these patients hypoventilate (CO₂ rises before O₂ falls). Waiting for hypoxia means waiting too long. Tachypnea alone is non-specific.

Q10. A 48-year-old woman with severe refractory AChR-Ab positive generalized MG fails to respond adequately to prednisone, azathioprine, MMF, and 3 cycles of plasma exchange. Which targeted biologic therapy is most specifically indicated for her condition?

A) Rituximab (anti-CD20)
B) Eculizumab (anti-C5)
C) Efgartigimod (FcRn inhibitor)
D) Tocilizumab (anti-IL-6)
E) Belimumab (anti-BAFF)

Answer: B - Eculizumab is FDA-approved specifically for AChR-Ab positive refractory generalized MG in adults who have failed conventional therapy. Its mechanism directly targets complement-mediated lysis of AChRs, the dominant pathogenic mechanism in AChR-Ab MG. Efgartigimod (C) is also an option (reduces total IgG including AChR-Ab) and is approved for AChR-positive gMG. Rituximab (A) is particularly effective in MuSK-MG, not primarily AChR-positive refractory disease. The question specifies AChR-Ab positive, making eculizumab the most targeted and specifically approved agent.

Summary Table: MG at a Glance

Domain	Key Points
Pathophysiology	Autoantibodies vs. AChR (most common); complement lysis is dominant mechanism; thymus plays central role
Antibody serology	AChR-Ab: 85-90% GMG; MuSK: 30-50% AChR-neg; LRP4: 1-3%; Titin/RyR: thymoma marker
Electrophysiology	RNS decrement >10% (low freq); SFEMG increased jitter - most sensitive (>95%)
Subtypes	Ocular; EOMG; LOMG; Thymomatous; MuSK; Seronegative
Symptomatic Rx	Pyridostigmine (NOT in MuSK)
Acute Rx	PLEX > IVIG for crisis; IVIG if PLEX unavailable
Long-term IS	Steroids + azathioprine/MMF; tacrolimus; rituximab (MuSK)
Targeted biologics	Eculizumab (AChR+ refractory); Efgartigimod (FcRn); Ravulizumab
Surgery	Thymectomy: mandatory (thymoma); recommended (AChR+ GMG, 18-65)
Crisis	FVC <20 mL/kg → intubate; PLEX preferred; hold pyridostigmine; treat precipitant
MG vs LEMS	MG: postsynaptic, decrement, no autonomic; LEMS: presynaptic, increment, SCLC, autonomic

*Sources: Bradley and Daroff's Neurology in Clinical Practice; Goldman-Cecil Medicine; Henry's Clinical Diagnosis and Management by Laboratory Methods; Tintinalli's Emergency Medicine; Washington Manual of Medical Therapeutics; Murray & Nadel's Respiratory Medicine. Recent evidence: Cochrane systematic review of rituximab for MG (PMID 40607605, 2025); network meta-analysis of novel biologics in MG (PMID 40346603, 2025).*That completes the full consultant-level teaching on Myasthenia Gravis. Here's what was covered:

The teaching includes 14 sections:

Definition and overview
Epidemiology (with HLA associations)
Pathophysiology (3 mechanisms of AChR destruction, thymic role)
Antibody subtypes (AChR, MuSK, LRP4, titin/RyR - with clinical correlations)
Clinical subtypes (Ocular, EOMG, LOMG, Thymomatous, MuSK, Seronegative)
Clinical presentation (ocular, bulbar, diurnal variation)
Diagnosis (clinical tests, serology, RNS, SFEMG, imaging)
Differential diagnosis (including the critical MG vs. LEMS comparison)
Treatment pyramid (pyridostigmine → PLEX/IVIG → immunosuppression → biologics → thymectomy)
Myasthenic crisis (triggers, crisis vs. cholinergic crisis, ventilation rules, management)
Special populations (pregnancy, elderly)
Monitoring and outcome measures (MGFA, MG-ADL, QMG)
MG vs. LEMS comparison table
Recent advances (eculizumab, efgartigimod, FcRn inhibitors, CAR-T, 2025 evidence)

10 consultant-level MCQs test: antibody sensitivity, cholinergic vs. myasthenic crisis, thymoma management, electrodiagnostics, MuSK-MG treatment, eculizumab mechanism, ocular MG prognosis, crisis treatment, ventilation triggers, and refractory MG biologics.

This is a shared conversation. Sign in to Orris to start your own chat.